Literature DB >> 17767980

Potential use an Actinobacillus pleuropneumoniae double mutant strain DeltaapxIICDeltaapxIVA as live vaccine that allows serological differentiation between vaccinated and infected animals.

Jinlin Liu1, Xia Chen, Liwen Lin, Chen Tan, Yan Chen, Yi Guo, Meilin Jin, Aizhen Guo, Weicheng Bei, Huanchun Chen.   

Abstract

Actinobacillus pleuropneumoniae is the causative agent of porcine pleuropneumonia, a highly contagious and often fatal disease. We have previously reported the construction and characterization of a single gene apxIIC deletion mutant HB04C(-) based on A. pleuropneumoniae serovar 7 which produces ApxII toxin and ApxIV. A precisely defined DeltaapxIICDeltaapxIVA double-deletion mutant of A. pleuropneumoniae was constructed based on HB04C(-) by transconjugation and counterselection, and the levels of virulence of the DeltaapxIIC single mutant and DeltaapxIICDeltaapxIVA double mutant were compared in an experimental infection in mice and pigs. The results demonstrated that the DeltaapxIICDeltaapxIVA double mutant strain was less virulent than HB04C(-). Despite attenuation of virulence, the DeltaapxIICDeltaapxIVA double mutant remains immunogenic and conferred a similar level of protective immunity to pigs against challenge with a lethal dose of a heterologous fully virulent standard serovar 1 strain of A. pleuropneumoniae. The results of the virulence study suggest that ApxIV is a critical virulence factor of A. pleuropneumoniae serovar 7 and is able to induce clinical disease, but it not required for efficient vaccination of pigs against A. pleuropneumoniae infection. Two weeks after the booster immunization, animals vaccinated with HB04C(-) were positive in the ApxIVAM-ELISA based on a recombinant GST-fusion protein GST-ApxIVAM as the solid-phase antigen while animals vaccinated with the DeltaapxIICDeltaapxIVA double mutant were negative. These data demonstrate that the double mutant DeltaapxIICDeltaapxIVA can be used as an effective live marker vaccine allowing serological differentiation between vaccinated and infected animals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17767980     DOI: 10.1016/j.vaccine.2007.07.053

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Cloning, expression, and characterization of TonB2 from Actinobacillus pleuropneumoniae and potential use as an antigenic vaccine candidate and diagnostic marker.

Authors:  Jinlin Liu; Yan Chen; Fangyan Yuan; Linlin Hu; Weicheng Bei; Huanchun Chen
Journal:  Can J Vet Res       Date:  2011-07       Impact factor: 1.310

2.  The live attenuated Actinobacillus pleuropneumoniae triple-deletion mutant ΔapxIC ΔapxIIC ΔapxIV-ORF1 strain, SLW05, Immunizes pigs against lethal challenge with Haemophilus parasuis.

Authors:  Shulin Fu; Jiwen Ou; Minmin Zhang; Juan Xu; Huazhen Liu; Jinlin Liu; Fangyan Yuan; Huanchun Chen; Weicheng Bei
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

3.  Population-based analysis of Actinobacillus pleuropneumoniae ApxIVA for use as a DIVA antigen.

Authors:  Ciaragh O'Neilla; Sophie C P Jones; Janine T Bossé; Conrad M Watson; Susanna M Williamson; Andrew N Rycroft; J Simon Kroll; Helen M Hartley; Paul R Langford
Journal:  Vaccine       Date:  2010-05-16       Impact factor: 3.641

4.  Immunoproteomic analysis of bacterial proteins of Actinobacillus pleuropneumoniae serotype 1.

Authors:  Wei Zhang; Jing Shao; Guangjin Liu; Fang Tang; Yan Lu; Zhipeng Zhai; Yang Wang; Zongfu Wu; Huochun Yao; Chengping Lu
Journal:  Proteome Sci       Date:  2011-06-26       Impact factor: 2.480

5.  Proteomic and immunoproteomic characterization of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae.

Authors:  Falk Fr Buettner; Sarah A Konze; Alexander Maas; Gerald F Gerlach
Journal:  Proteome Sci       Date:  2011-04-20       Impact factor: 2.480

6.  Construction and immunization with double mutant ΔapxIBD Δpnp forms of Actinobacillus pleuropneumoniae serotypes 1 and 5.

Authors:  Hoai Thu Dao; Quang Lam Truong; Van Tan Do; Tae Wook Hahn
Journal:  J Vet Sci       Date:  2020-03       Impact factor: 1.672

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.